Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lemaitre Vascular (LMAT) Gains from Investment Securities (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed Gains from Investment Securities for 13 consecutive years, with $697973.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 2.98% to $697973.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $697973.0, a 2.98% decrease, with the full-year FY2025 number at $697973.0, down 2.98% from a year prior.
  • Gains from Investment Securities was $697973.0 for Q4 2025 at Lemaitre Vascular, up from $741.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $846754.0 in Q4 2021 to a low of -$176000.0 in Q3 2022.
  • A 5-year average of $190576.4 and a median of $24000.0 in 2023 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: surged 4327.24% in 2021, then plummeted 111.81% in 2022.
  • Lemaitre Vascular's Gains from Investment Securities stood at $846754.0 in 2021, then tumbled by 111.81% to -$100000.0 in 2022, then surged by 248.12% to $148115.0 in 2023, then skyrocketed by 385.73% to $719436.0 in 2024, then decreased by 2.98% to $697973.0 in 2025.
  • Per Business Quant, the three most recent readings for LMAT's Gains from Investment Securities are $697973.0 (Q4 2025), $741.0 (Q2 2025), and $741.0 (Q1 2025).